Prospective evaluation of the effect of 3 days of post-chemotherapy dexamethasone on patient reported symptoms in gynecologic oncology patients treated with carboplatin and paclitaxel.

• DOI: 10.1200/jco.2024.42.16_suppl.5618
• Publication Date: 2024-06-06T20:15:45Z
• Authors: Hayley Hart; Christopher Morse; Thomas C. Krivak; Eirwen Murray Miller; Sarah Crafton; Alyssa Wield; Alexander Olawaiye; Ali Imran Amjad; Emily Graham; Tammy Li; Heather English; Donna Marie Kinzler; John Nakayama
• Keywords: Carboplatin; Gynecologic oncology; Gynecologic cancer

5618 Background: Chemotherapy is associated with many adverse side effects including nausea, myalgia, and emotional stress. Some providers recommend three days of dexamethasone (supplemental dexamethasone) following chemotherapy in an effort to mitigate these toxicities. This study seeks determine if supplemental affects patient-reported outcomes patients receiving carboplatin paclitaxel. Methods: Patients gynecologic malignancies paclitaxel every 3 weeks were eligible. In this prospective case-control study, (cases) (8mg once daily x starting on post-chemotherapy day 1) compared those that did not receive delayed (controls). Decision for was based provider’s discretion. The FACT-G7, a validated survey assessing the impact patients’ quality life, administered by telephone one week after each cycle up 6 cycles. Pain during 1-3 also assessed additional question. FACT-G7 composite score our primary outcome interest. student’s t-test used compare average pain scores between cases controls at point. Results: Fifty-two enrolled, 26 received not. At interim analysis, 94% subjects have completed all time points. initial response rate 98.0%. (Table) significantly higher, corresponding less symptoms, treated cycles 4-6. lower group (p=.0083). Conclusions: Supplemental improves outcomes. improvement limited 4-6, suggesting possible mitigation cumulative toxicities.[Table: see text]